ANI Pharmaceuticals (ANIP) Q4 2025 earnings review
Crossing the $1B Threshold, But Product Mix Squeezes Margins
ANI Pharmaceuticals capped a transformational 2025 with an excellent fourth quarter. Total net revenues grew 29.6% year-over-year to $247.1 million, driven by an unstoppable surge in Cortrophin Gel (+87.6% YoY) and robust Generics performance. However, this explosive top-line growth is coming with a cost: shifting product mix toward royalty-bearing Cortrophin and partnered generics drove a steep deceleration in non-GAAP gross margins to 59.6% from 63.5% a year ago. Management initiated aggressive FY26 guidance, projecting over $1 billion in revenue and marking a decisive shift as the Rare Disease segment is expected to command a 60% revenue share. The volume turnaround is incredibly impressive, but investors must accept a slightly structurally lower margin profile going forward.
🐂 Bull Case
Cortrophin Gel sales accelerated 87.6% YoY in Q4, reaching $347.8M for the full year. The ongoing expansion into acute gouty arthritis and the introduction of a pre-filled syringe are structurally expanding the addressable ACTH market.
Despite typically lumpy industry dynamics, ANI's Generics business proved highly resilient, growing 28.2% in Q4 and generating essential cash flow to fund Rare Disease expansion.
🐻 Bear Case
Because Cortrophin Gel carries a high-20% royalty rate to Merck, and recent generic launches include profit-sharing agreements, ANI's gross margin has structurally stepped down to the ~60% range.
The ILUVIEN/YUTIQ assets (Alimera acquisition) ended 2025 at $74.9M, missing the initial $97M-$103M expectations set early in the year. The FY26 growth guide of just 4-11% shows management sees a slow, rather than V-shaped, recovery.
⚖️ Verdict: 🟢
Bullish. The strategic transformation into a Rare Disease powerhouse is succeeding. While margin compression is a mathematical reality of their royalty obligations, the absolute dollar growth in EBITDA (+47% YoY in FY25) more than compensates for the margin percentage decline.
Key Themes
Cortrophin Gout Focus Demands Aggressive Investment
Management is leaning heavily into the acute gouty arthritis indication—which already comprises >15% of Cortrophin use. In a major strategic move, ANI announced a 90-person dedicated sales force expansion deploying in mid-2026 targeting podiatrists and primary care. This is a massive resource commitment indicating high confidence in the Phase 4 clinical trial data and the long-term total addressable market.
Structural Gross Margin Compression
Decelerating/Negative. Q4 Non-GAAP gross margin compressed sharply to 59.6% from 63.5% in 24Q4. This is not an operational failure, but rather a mix shift: Cortrophin Gel requires significant royalty payments (expected in the high-20% range for 2026), and the successful partnered generic product carries a profit-share. The FY26 guidance of 59.3%-60.3% confirms this lower margin tier is the new normal.
ILUVIEN's Delayed Turnaround
Stable/Sluggish. Q4 ILUVIEN/YUTIQ revenues of $19.8M represent only a modest sequential improvement. The company closed out 2025 with $74.9M in retina revenues—far below the $97-$103M management expected in early 2025. Persistent Medicare Part B foundation funding gaps severely hampered the segment. Management has effectively labeled this a 'reset,' and the muted 2026 growth target suggests alternative access channels (Part D) will take significant time to scale.
Geopolitical De-risking: The U.S. Manufacturing Shield
In a macro environment increasingly focused on tariffs and supply chain security, ANI's footprint is a distinct advantage. With 93% of finished goods manufactured in the United States and only ~5% of revenues carrying direct reliance on China for APIs, ANI is insulated from potential bipartisan trade actions that could disrupt competitors.
Generics Outpacing Base Industry Growth
Accelerating. Q4 Generics revenue hit $100.8M (+28.2% YoY), bringing FY25 to $384.1M (+27.6%). This performance severely undercuts the narrative that generics are a melting ice cube. By targeting complex products, competitive generic therapies (CGTs), and opportunistic partnerships, ANI continues to extract outsized cash flows from this segment to bankroll its rare disease ambitions.
Other KPIs
Accelerating. Grew 30.6% YoY. For the full year, Adjusted EBITDA hit $229.8 million (+47.3% YoY). Despite the aforementioned gross margin compression, exceptional top-line volume flow-through resulted in massive bottom-line dollar growth.
Stable and highly generative. This enabled ANI to end the year with $285.6 million in unrestricted cash, providing ample dry powder to either execute on further Rare Disease M&A or fund the substantial SG&A required for the 90-person gout sales force expansion.
Accelerating. An increase of 28.1% YoY. This reflects the intentional, heavy investment in the Rare Disease commercial infrastructure. With the gout sales force deployment coming in mid-2026, investors should expect SG&A to remain elevated.
Guidance
Decelerating growth rate but massive absolute scale. The midpoint ($1.085B) implies ~23% YoY growth. This represents a deceleration from the 43.8% YoY growth achieved in FY25, but successfully crosses the psychological $1B revenue threshold.
Decelerating but incredibly strong. The midpoint implies ~60% YoY growth versus the $347.8M delivered in FY25 (which was a 75% YoY expansion). Cortrophin alone will account for roughly half of the company's total revenue.
Stable/Sluggish. Implies just 4-11% YoY growth over the $74.9M achieved in FY25. This cautious outlook highlights management's reluctance to bake in a major recovery in Medicare foundation co-pay support.
Decelerating. Implies 20-26% YoY growth versus the 47% achieved in FY25. The growth compression relative to revenue highlights the twin headwinds of the lower structural gross margin (59.3-60.3% guide) and the upcoming SG&A ramp for the gout sales force expansion.
Key Questions
Gout Sales Force Economics
With the addition of 90 new commercial roles dedicated to acute gouty arthritis in mid-2026, what is the expected timeline for this specific expansion to reach break-even profitability?
ILUVIEN Part D Access Timeline
Guidance for ILUVIEN is highly conservative. How exactly is the transition to alternative Medicare Part D specialty pharmacy channels progressing, and when will we see a material volume inflection from this effort?
Generics Pipeline Durability
Given the phenomenal 28% growth in Generics during Q4 driven partly by a partnered launch, what is the baseline growth expectation for the Generics segment in 2026 as competitive entrants normalize pricing on 2025's key launches?
Capital Allocation Strategy
With nearly $286 million in cash and generating strong operating cash flow, are you prioritizing Rare Disease M&A, debt reduction, or internal pipeline development for capital deployment in 2026?